<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>It is currently estimated that more than 300 million people have <z:hpo ids='HP_0000833'>impaired glucose tolerance</z:hpo> (IGT), putting them at increased risk for type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (T2DM) and its adverse consequences </plain></SENT>
<SENT sid="1" pm="."><plain>In addition, many others are at risk on the basis of a family history of T2DM, <z:hpo ids='HP_0001513'>obesity</z:hpo>, <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> and <z:hpo ids='HP_0000822'>hypertension</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Screening for risk should include both blood <z:chebi fb="105" ids="17234">glucose</z:chebi> testing in high-risk populations and prescreening (e.g. by questionnaire, waist circumference measurement) to identify high-risk individuals in overall low-risk populations; these individuals should then undergo <z:chebi fb="105" ids="17234">glucose</z:chebi> testing </plain></SENT>
<SENT sid="3" pm="."><plain>Fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> measurement cannot diagnose IGT; the preferred definite test for diagnosis is oral <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance testing </plain></SENT>
</text></document>